Inhibitory effect of argatroban on thrombin-antithrombin III complex after percutaneous transluminal coronary angioplasty.
Sakamoto
S
S
Hirase
T
T
Suzuki
S
S
Tsukamoto
T
T
Miki
T
T
Yamada
T
T
Matsuo
T
T
D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000990:Antithrombin III / Q000494:pharmacology*; D000991:Antithrombins / Q000494:pharmacology* / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives; D015415:Biomarkers; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000097:blood / Q000628:therapy*; D010447:Peptide Hydrolases / Q000494:pharmacology*; D010875:Pipecolic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D013449:Sulfonamides; D013917:Thrombin / Q000378:metabolism; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D000991:Antithrombins; D015415:Biomarkers; D010875:Pipecolic Acids; D013449:Sulfonamides; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D006493:Heparin; D001120:Arginine; D010447:Peptide Hydrolases; D013917:Thrombin; C031942:argatroban